Peregrine Pharma (PPHM) Posts Q2 Loss of 6c, Wider Than Estimated
PPHM Hot Sheet
Revenue Growth %: +13.9%Financial Fact:
Government contract revenue: 0
Today's EPS Names:
TARO, BRLI, TLB, More
Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) reports Q2 loss of $0.06, versus the analyst estimate of ($0.01). Revenue for the quarter was $6.90 million, which compares to the estimate of $6.39 million.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Semtech Corp (SMTC) Misses Q1 EPS by 4c; Guides Q2
- Tsakos Energy Navigation Ltd. (TNP) Posts Narrower than Expected Q1 Loss
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
